• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Multiple Endocrine Neoplasia

Multiple Endocrine Neoplasia - 16 Studies Found

Active, not recruiting : Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
: Multiple Endocrine Neoplasia
: 2007-07-12
: Behavioral: Questionnaire Mailed packets including cover letter describing purpose of study, study quest
Completed : Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
: Multiple Endocrine Neoplasia Syndromes
: 2017-02-07
: Behavioral: Questionnaires Multiple Endocrine Neoplasia Sy
Completed : Vancomycin Associated Red Man Syndrome (RMS)
: Red Man Syndrome
: 2009-01-14
Completed : Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
: Multiple Endocrine Neoplasia
: 2017-02-07
Completed : Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
:
  • Multiple Endocrine Neoplasia
  • Pancreatic Neuroendocrine Tumors : 2017-02-13
    :
    • Other: Genome Sequencing Analy

Completed : Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
:
  • Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia Type 2
    : 2011-08-26
Active, not recruiting : Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
:
  • Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia Type 2
    : 2007-08-08
    : Drug: Vandetanib once daily continuously (28 day cycles)
Not yet recruiting : Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
: Pancreatic Neuroendocrine Tumors in MEN1
: 2016-03-02
: Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied.
Completed : High Dose Somatostatin Analogues in Neuroendocrine Tumors
:
  • Respiratory Tract Neoplasms
  • Thymic Neoplasms
  • Pancreatic Ne
    : 2009-10-05
    : Drug: Octreotide-LAR Octreotide-LAR 30 mg administered every 21 days until progression
Terminated : A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
:
  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Adrenal Gland Tumor
    : 2009-07-23
    :
    • Drug: pertuzumab 840 mg, 420 m

Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.